These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 33088647)

  • 21. Insulin and oral agents for managing cystic fibrosis-related diabetes.
    Onady GM; Stolfi A
    Cochrane Database Syst Rev; 2016 Apr; 4():CD004730. PubMed ID: 27087121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Repaglinide, potentially a therapeutic improvement for diabetes mellitus type 2].
    Rutten GE
    Ned Tijdschr Geneeskd; 2001 Aug; 145(32):1547-50. PubMed ID: 11525087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus.
    Malaisse WJ
    Treat Endocrinol; 2003; 2(6):401-14. PubMed ID: 15981944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control.
    Chisalita SI; Lindström T; Eson Jennersjö P; Paulsson JF; Westermark GT; Olsson AG; Arnqvist HJ
    Acta Diabetol; 2009 Mar; 46(1):35-42. PubMed ID: 18777156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug interactions of meglitinide antidiabetics involving CYP enzymes and OATP1B1 transporter.
    Pakkir Maideen NM; Manavalan G; Balasubramanian K
    Ther Adv Endocrinol Metab; 2018; 9(8):259-268. PubMed ID: 30181852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes.
    Moses R
    Expert Opin Pharmacother; 2000 Dec; 1(7):1455-67. PubMed ID: 11249478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Repaglinide: a new short-acting insulinotropic agent for the treatment of type 2 diabetes.
    Owens DR
    Eur J Clin Invest; 1999 Jun; 29 Suppl 2():30-7. PubMed ID: 10383608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of hypoglycemia associated with repaglinide combined with clopidogrel, a retrospective cohort study.
    Akagi Y; Iketaki A; Kimura H; Matsudaira Y; Yoshida T; Nishimura T; Kawano Y; Mano Y; Shigematsu E; Ujihara M
    J Pharm Health Care Sci; 2020; 6():5. PubMed ID: 32206324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.
    Niemi M; Neuvonen PJ; Kivistö KT
    Clin Pharmacol Ther; 2001 Jul; 70(1):58-65. PubMed ID: 11452245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical experience with repaglinide in patients with non-insulin-dependent diabetes mellitus.
    Shapiro MS; Abrams Z; Lieberman N
    Isr Med Assoc J; 2005 Feb; 7(2):75-7. PubMed ID: 15729954
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repaglinide--a new compound for the treatment of patients with type 2 diabetes.
    Wolffenbuttel BH
    Neth J Med; 1999 Nov; 55(5):229-34. PubMed ID: 10593133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin and oral agents for managing cystic fibrosis-related diabetes.
    Onady GM; Stolfi A
    Cochrane Database Syst Rev; 2013 Jul; (7):CD004730. PubMed ID: 23893261
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical pharmacokinetics and pharmacodynamics of repaglinide.
    Hatorp V
    Clin Pharmacokinet; 2002; 41(7):471-83. PubMed ID: 12083976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
    Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
    Basic Clin Pharmacol Toxicol; 2005 Oct; 97(4):249-56. PubMed ID: 16176562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes.
    Kudo T; Hisaka A; Sugiyama Y; Ito K
    Drug Metab Dispos; 2013 Feb; 41(2):362-71. PubMed ID: 23139378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
    Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
    Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacology and clinical experience with repaglinide.
    Massi-Benedetti M; Damsbo P
    Expert Opin Investig Drugs; 2000 Apr; 9(4):885-98. PubMed ID: 11060717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide.
    Bidstrup TB; Damkier P; Olsen AK; Ekblom M; Karlsson A; Brøsen K
    Br J Clin Pharmacol; 2006 Jan; 61(1):49-57. PubMed ID: 16390351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nateglinide: A structurally novel, short-acting, hypoglycemic agent.
    Norman P; Rabasseda X
    Drugs Today (Barc); 2001 Jun; 37(6):411-426. PubMed ID: 12764427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Absorption, metabolism and excretion of a single oral dose of (14)C-repaglinide during repaglinide multiple dosing.
    van Heiningen PN; Hatorp V; Kramer Nielsen K; Hansen KT; van Lier JJ; De Merbel NC; Oosterhuis B; Jonkman JH
    Eur J Clin Pharmacol; 1999 Sep; 55(7):521-5. PubMed ID: 10501822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.